Therefore, it is very important to find new targets in the treatment of COAD, especially the integrin family, as existing studies have not explored the correlation of ITGβ3 gene expression in COAD with clinical data, and there is insufficient data to illustrate the prospects of anti-ITGβ3 drugs in the treatment of COAD. Here, ITGB3 is linked to colon adenocarcinoma.